Key facts
- This page summarizes SoYoung Kwon's Form 4 filing for Aptevo Therapeutics Inc. (APVO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2022, 16:14.
SoYoung Kwon - 09 Aug 2022 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)
- Reporting relationship
- SVP, GC and Corporate Affairs
- Issuer ticker
- APVO
- Reported as of
- 09 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2022, 16:14:41 UTC
- Prior SEC filing
- 07 Jun 2022
- Next SEC filing
- 07 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- SoYoung Kwon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
SoYoung Kwon filed Form 4 for Aptevo Therapeutics Inc. (APVO) on 10 Aug 2022.
Change
- Previous filing in this sequence was filed on 07 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APVO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +18,750
- Change %
- Price
- $0.000000
- Shares after
- 18,750
- Date
- 09 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,750
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
Footnote F2
The RSUs vest in two approximately equal annual installments beginning on August 8, 2023.